Swedish Orphan Biovitrum

Contact
sobi.com
+46 8 697 20 00

Swedish Orphan Biovitrum

Berzelius väg 8
112 76 Solna
Sweden
+46 8 697 20 00
sobi.com
Contact
Profile News
Contact

About Swedish Orphan Biovitrum

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, our revenue amounted to SEK 15.3 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm.

Read more about Swedish Orphan Biovitrum
Facts about Swedish Orphan Biovitrum
  • Focus : Manufacturer
  • Industry : Pharma

News about Swedish Orphan Biovitrum

Swedish Orphan Biovitrum

21-Jan-2016 | research and development

Sobi's Orfadin® oral suspension granted European patent

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® ( ...

Read news
Swedish Orphan Biovitrum

17-Apr-2015 | research and development

Sobi receives orphan drug designation for Elocta in Switzerland

Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed ...

Read news
Swedish Orphan Biovitrum

04-Mar-2015 | research and development

Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study

Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, ...

Read news
Swedish Orphan Biovitrum

03-Feb-2015 | research and development

Xiapex approved by the EU Commission for the treatment of Peyronie's disease

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of ...

Read news
Swedish Orphan Biovitrum

23-Dec-2014 | research and development

Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease

Swedish Orphan Biovitrum AB and partner Auxilium Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Read news
Swedish Orphan Biovitrum

27-Jun-2014 | research and development

Sobi files for EU approval of Xiapex for Peyronies disease

Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc.announced that Sobi has filed for an extension of the label for Xiapex® ( ...

Read news
Swedish Orphan Biovitrum

28-May-2014 | people

Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that Kirsti Gjellan has been appointed Senior Vice President Manufacturing Operations. Gjellan joins ...

Read news
Swedish Orphan Biovitrum

10-Jan-2013 | science

FDA approves Kineret for the treatment of NOMID

Sobi announced that the US Food and Drug Administration (FDA) has approved Kineret® (anakinra) for the treatment of children and adults with neonatal-onset ...

Read news
Show more news about Swedish Orphan Biovitrum

Here you will find Swedish Orphan Biovitrum